Good Therapeutics, founded in 2016 by John Mulligan, Ph.D., was acquired by Roche in 2022 for $250 million upfront plus potential milestone payments. Even better, Mulligan and company retained their platform and the ability to mine it for innovative drugs to fight cancer and other diseases.
RiverVest led the Series A investment in Standard Bariatrics in 2018. The surgical device company was acquired by Teleflex in 2022 for $170 million plus additional milestone payments.
Mirum was founded upon a drug compound that RiverVest helped develop through Lumena, a Fund II company acquired in 2014. After the acquirer deprioritized the drug, the Lumena team bought it back so they could finish what they started — getting kids with rare liver disease the relief they need.
RiverVest co-founded and seed funded Lumena and built a clinical strategy to fast-track its lead drug compound through clinical trials. The company was acquired by Shire in 2014.
Subscribe to our newsletter